The FDA’s Office of Prescription Drug Promotion reviewed promotional material about the drug and said it misrepresented its efficacy. The material stated Breztri Aerosphere saw a “difference observed in time to all-cause mortality (over 52 weeks),” but the FDA said this is misleading since no COPD medications have proven a positive result on all-cause mortality.
This misbranding is in violation of the Federal Food, Drug, and Cosmetic Act and “makes its distribution violative,” the warning letter said. The letter is dated Aug. 4 and was posted to the agency’s website on Aug. 15.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
